Aggregation risk prediction for antibodies and its application to biotherapeutic development

mAbs

Volumn 7, Issue 2, 2015, Pages 352-363

  Obrezanova, Olga ^a   Arnell, Andreas ^a   De La Cuesta, Ramón Gómez ^b,c   Berthelot, Maud E ^b   Gallagher, Thomas R A ^a   Zurdo, Jesús ^b   Stallwood, Yvette ^a  

^a Applied Protein Services Lonza Biologics   (United Kingdom)

^b Cancer Research UK   (United Kingdom)

^c Babraham Research Campus   (United Kingdom)

Author keywords

Aggregation; Aggregation prediction; Biotherapeutics; Developability assessment; Monoclonal antibody

Indexed keywords

ANTIBODY; PROTEIN AGGREGATE;

ALGORITHM; ARTICLE; BIOLOGICAL THERAPY; CONTROLLED STUDY; DRUG DEVELOPMENT; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOLECULE; PHYSICAL CHEMISTRY; PREDICTION; PREDICTIVE VALUE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; RISK FACTOR; VALIDATION PROCESS; CHEMISTRY;

ALGORITHMS; ANTIBODIES; HUMANS; PROTEIN AGGREGATES;

EID: 84924586477     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1007828     Document Type: Article

References (37)

1. Zurdo J. Developability assessment as an early de-risking tool for biopharmaceutical development. Pharmaceutical Bioprocessing 2013; 1:29-50; http://dx.doi. org/10.4155/pbp.13.3
2. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J 2006; 8:E501-7; PMID:17025268; http://dx.doi.org/10.1208/aapsj 080359
3. Seidl A, Hainzl O, Richter M, Fischer R, Böhm S, Deutel B, Hartinger M, Windisch J, Casadevall N, London GM, et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res 2012; 29:1454-67; PMID:22094831; http://dx.doi.org/ 10.1007/s11095-011-0621-4
4. Vazquez-Ray M, Lang D. Aggregates in monoclonal antibody manufacturing processes. Biotechnol Bioeng 2011; 108:1494-1508; PMID:21480193; http://dx. doi.org/10.1002/bit.23155
5. Belli M, Ramazzotti M, Chiti F. Prediction of amyloid aggregation in vivo. EMBO Rep 2011; 12:657-63; PMID:21681200; http://dx.doi.org/10.1038/embor. 2011.116
6. Agrawal NJ, Kumar S,Wang X,Helk B, Singh SK, Trout BL. Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation prone regions. J Pharm Sci 2011; 100:5081-95; PMID:21789769; http://dx.doi.org/10.1002/jps.22705
7. Wang X, Das TK, Singh SK, Kumar S. Potential aggregation prone regions in biotherapeutics: a survey of commercial monoclonal antibodies. mAbs 2009; 1:254-67; PMID:20065649; http://dx.doi.org/ 10.4161/mabs.1.3.8035
8. Chennamsetty N, Helk B, Voynov V, Kayser V, Trout BL. Aggregation-prone motifs in human immunoglobulin G. J Mol Biol 2009; 391:404-13; PMID:19527731; http://dx.doi.org/10.1016/j.jmb.2009.06.028
9. Lauer TM, Agrawal NJ, Chennamsetty N, Egodage K, Helk B, Trout BL. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci 2012; 101:102-15; PMID:21935950; http:// dx.doi.org/10.1002/jps.22758
10. Szita N, Boccazzi P, Zhang Z, Boyle P, Sinskey AJ, Jensen KF. Development of a multiplexed microbioreactor system for high-throughput bioprocessing. Lab Chip 2005; 5:819-26; PMID:16027932; http://dx.doi.org/ 10.1039/b504243g
11. Duetz WA, Rüedi L, Hermann R, O'Connor K, Büchs J, Witholt B. Methods for intense aeration, growth, storage, and replication of bacterial strains in microtiter plates. Appl Environ Microbiol 2000; 66:2641-6; PMID:10831450; http://dx.doi.org/10.1128/AEM.66. 6.2641-2646.2000
12. Zurdo J, Michael R, Stallwood Y, Hedman K, Aastrup T. Improving the developability of biopharmaceuticals. Inno Pharma Technol 2011; 37:34-40.
13. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The protein data bank. Nucleic Acids Res 2000; 28:235-42. http://www.rcsb.org; PMID:10592235; http://dx.doi. org/10.1093/nar/28.1.235
14. Chemical Abstracts Service. SciFinder [Internet]. Columbus (OH): American Chemical Society (US), Chemical Abstracts Service; c2014 [cited 2014 Oct 7]. Available from: http://www.cas.org/
15. Honegger A, Plückthun A. The influence of the buried glutamine or glutamate residue in position 6 on the structure of immunoglobulin variable domains. J Mol Biol 2001; 309:687-99; PMID:11397089; http://dx. doi.org/10.1006/jmbi.2001.4664
16. Zhou P, Chen X, Wu Y, Shang Z. Gaussian process: an alternative approach for QSAM modelling of peptides. Amino Acids 2010; 38:199-212; PMID:19123053; http://dx.doi.org/10.1007/s00726-008-0228-1
17. Breiman L. Random forests. Machine Learning 2001; 45:5-32; http://dx.doi.org/10.1023/A:1010933404324
18. MacKay D. Information theory, inference, and learning algorithms. Cambridge: Cambridge University Press; 2003. 640 p.
19. Obrezanova O, Csanyi G, Gola JM, Segall MD. Gaussian processes: a method for automatic QSAR modeling 47:1847-57; PMID:17602549; http://dx.doi.org/ 10.1021/ci7000633
20. Freund Y, Schapire RE. A decision-theoretic generalization of on-line learning and an application to boosting. J Computer System Sci 1997; 55:119-39; http://dx. doi.org/10.1006/jcss.1997.1504
21. Padlan EA, Silverton EW, Sheriff S, Cohen GH, Smith-Gill SJ, Davies DR. Structure of an antibodyantigen complex: crystal structure of the HyHEL-10 Fab-lysozyme complex. Proc Natl Acad Sci U S A 1989; 86:5938-42; PMID:2762305; http://dx.doi.org/ 10.1073/pnas.86.15.5938
22. Fischmann TO, Bentley GA, Bhat TN, Boulot G, Mariuzza RA, Phillips SE, Tello D, Poljak RJ. Crystallographic refinement of the three-dimensional structure of the Fab D1.3-lysozyme complex at 2.5-A resolution. J Biol Chem 1991; 266:12915-20; PMID:1712773
23. Fan ZC, Shan L, Goldsteen BZ, Guddat LW, Thakur A, Landolfi NF, Co MS, Vasquez M, Queen C, Ramsland PA, et al. Comparison of the three-dimensional structures of a humanized and a chimeric Fab of an anti-gamma-interferon antibody. J Mol Recognit 1999; 12:19-32; PMID:10398393; http://dx.doi.org/ 10.1002/(SICI)1099-1352(199901/02)12:1%3c19:: AID-JMR445%3e3.0.CO;2-Y
24. Van Walle I, Gansemans Y, Parren PW, Stas P, Lasters I. Immunogenicity screening in protein drug development. Expert Opin Biol Ther 2007; 7:405-18; PMID:17309332; http://dx.doi.org/10.1517/14712598. 7.3.405
25. Lonza Biologics. EpibaseTM Immunogenicity Assessment Page [Internet]. Cambridge, UK: Lonza Biologics; 2014 [cited 2014 Oct 7]. Available from: http://www.lonza.com/custom-manufacturing/ development-technologies/protein-and-vaccine-development-services/immunogenicity-platforms.aspx
26. Fernandez-Escamilla A-M, Rousseau F, Schymkowitz J, Serrano L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol 2004; 22:1302-6; PMID:15361882; http://dx.doi.org/10.1038/nbt1012
27. Tartaglia GG, Cavalli A, Pellarin R, Caflisch A. Prediction of aggregation rate and aggregation-prone segments in polypeptide sequences. Protein Sci 2005; 14:2723-34; PMID:16195556; http://dx.doi.org/ 10.1110/ps.051471205
28. Zurdo J. Surviving the valley of death. Eur Biopharmaceutical Rev 2013; 195:50-4.
29. Wang P, Sidney J, Kim Y, Sette A, Lund O, NielsenM, Peters B. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics 2010; 11:568-79; PMID:21092157; http://dx.doi.org/ 10.1186/1471-2105-11-568
30. Yang X, Xu W, Dukleska S, Benchaar S, Mengisen S, Antochshuk V, Cheung J, Mann L, Babadjanova Z, Rowand J, et al. Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies. mAbs 2013; 5:787-94; PMID:23883920; http://dx.doi.org/10.4161/mabs. 25269
31. Strohl WR, Strohl LM. Therapeutic antibody engineering. Cambridge: Woodhead Publishing Limited; 2012. Chapter 16, Development issues: antibody stability, developability, immunogenicity and comparability; p. 377-403.
32. Sathish H, Angell N, Lowe D, Shah A, Bishop S. Application of biophysics to the early developability assessment of therapeutic candidates and its application to enhance developability properties. In: Narhi LO, editor. Biophysics for therapeutic protein development. New York: Springer; 2013. Chapter 6, p. 127-146.
33. Alavattam S, Demeule B, Liu J, Yadav S, Cromwell M, Shire SJ. Biophysical analysis in support of development of protein pharmaceuticals. In: Narhi LO, editor. Biophysics for therapeutic protein development. New York: Springer; 2013. Chapter 8, p. 173-204.
34. MathWorks Inc. MATLAB (Release R2012b) [Computer software]. Natick: MathWorks Inc.; 2012.
35. Hellberg S, Sjöström M, Skagerberg B, Wold S. Peptide quantitative structure-activity relationships, a multivariate approach. J Med Chem 1987; 30:1126-35; PMID:3599020; http://dx.doi.org/10.1021/ jm00390a003
36. Accelrys Software Inc. Discovery Studio Modeling Environment (Release 3.5) [Computer software]. San Diego, USA: Accelrys Software Inc. (Biovia company); 2012.
37. Almagro JC, Beavers MP, Hernandez-Guzman F, Maier J, Shaulsky J, Butenhof K, Labute P, Thorsteinson N, Kelly K, Teplyakov A, et al. Antibody modeling assessment. Proteins 2011; 79:3050-66; PMID:21935986; http://dx.doi.org/10.1002/prot.23130